1. Яхно Н.Н., Кукушкин М.Л. Боль (практическое руководство для врачей). М.: Издательство РАМН, 2012.
2. Schug S, Manopas A. Update on the role of non-opioids for postoperative pain treatment. Best Pract Res Clin Anaesthesiol 2007; 21 (1): 15–30.
3. Camu F. The role of COX-2 inhibitors in pain modulation. Drug 2003; 63 (Suppl.): 1–7.
4. Mehta V, Johnston A, Cheung R et al. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clin Pharmacol Ther 2008; 83 (3): 430–5.
5. Dembo G, Park S, Kharasch E. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005; 102 (2): 409–15.
6. Bianchi M, Martucci C, Ferrario P et al. Increased Tumor Necrosis Factor- and Prostaglandin E2 Concentrations in the Cerebrospinal Fluid of Rats with Inflammatory Hyperalgesia. The Effects of Analgesic Drugs. Anesth Analg 2007; 104: 949–54.
7. Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects. Anesthesiology 2005; 102: 1249–60.
8. Elia N, Lysakowski C, Tramèr M. Does Multimodal Analgesia with Acetaminophen, Non-steroidal Antiinflammatory Drugs, or Selective Cyclooxygenase-2 Inhibitors and Patient-controlled Analgesia Morphine Offer Advantages over Morphine Alone? Meta-analyses of Randomized Trials. Anesthesiology 2005; 103 (6): 1296–304.
9. Lamplot J, Wagner E, Manning D. Multimodal Pain Management in Total Knee Arthroplasty. A Prospective Randomized Controlled Trial. J Arthroplasty 2013; pii: S0883–5403(13)00418-X. doi: 10.1016/j.arth.2013.06.005. [Epub ahead of print]
10. White P, Raeder J, Kehlet H. Ketorolac: its role as part of a multimodal analgesic regimen. Anesth Analg 2012; 114 (2): 250–4.
11. DeOliveira G, Agarwal D, Benzon H. Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials. Anesth Analg 2012; 114 (2): 424–33.
12. Oliveri L, Jerzewski K, Kulik A. Black Box Warning: Is Ketorolac Safe for Use After Cardiac Surgery? J Cardiothorac Vasc Anesth 2013; pii: S1053–0770(13)00424–2. doi: 10.1053/j.jvca.2013.07.014. [Epub ahead of print]
13. Maheshwari A, Blum Y, Shekhar L et al. Multimodal pain management after total hip and knee arthroplasty at the Ranawat Orthopaedic Center. Clin Orthop Relat Res 2009; 467: 1418–23.
14. Helin-Salmivaara A, Saarelainen S, Gronroos J et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scand J Gastroenterol 2007; 42: 923–32.
15. Fiorucci S, Distrutti E. COXIBs, CINODs and H2S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs. Curr Med Chem 2011; 18 (23): 3494–505.
16. Hunt R, Harper S, Watson D et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98 (8): 1725–33.
17. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465–73.
18. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинич. рекомендации. М.: ЭКО-ПРЕСС, 2009.
19. Silverstein F. New strategies for the prevention of serious upper GI complication from NSAIDs: lessons from the MUCOSA trial. New stand Arth Care 1996; 5: 2–6.
20. Acevedo E, Castaneda O, Ugaz M et al. Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. Scand J Rheumatol 2001; 30: 19–24.
21. Roberts D, Miner P. Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease. Drug Health Patient Saf 2011; 3: 1–8.
22. Gigante A, Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. Clin Drug Investig 2012; 32 (4): 221–33.
23. Bello A. DUEXIS® (ibuprofen 800 mg, famotidine 26,6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug. Ther Adv Musculoskelet Dis 2012; 4 (5): 327–39.
24. Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep 2008; 10 (1): 43–8.
25. Lanas A. Role of nitric oxide in the gastrointestinal tract. Arthritis Research & Therapy 2008; 10 (Suppl. 2): S4 doi:10.1186/ar2465
26. Keeble J, Moore P. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002; 137: 295–310.
27. Lanas A, García-Rodríguez LA, Arroyo MT et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102 (3): 507–15.
28. Lohmander LS, McKeith D, Svensson O et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005; 64: 449–56.
29. Cordrey LJ. Tolmetin sodium, a new anti-arthritis drug: double-blind and long-term studies.  J Am Geriatr Soc 1976; 24 (10): 440–6.
30. McEvoy GK. AHFS Drug Information 2007. ed. Tolmetin. Bethesda, MD: American Society of Health-System Pharmacists; 2007: 2118–22.
31. Coruzzi G, Coppelli G, Spaggiari S et al. Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible aastric nitric oxide svnthase. Dig Liver Dis 2002; 34 (6): 403–10.
32. Tubaro E, Belogi L, Mezzadri CM. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug. Eur J Pharmacol 2000; 387: 233–44.
33. Morini G, Guaita E, Lazzaretti M et al. Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs. Digestion 2003; 68 (2–3): 124–32.
34. Riezzo G, Chiloiro M, Montanaro S. Protective effect of amtolmetin guacyl versus placebo diclofenac and misoprostol in healthy volunteers evaluated as gastric electrical activity in alcohol-induced stomach damage. Dig Dis Sci 2001; 46 (8): 1797–804.
35. Tavella A, Ursini G. A clinical study on the anti-inflammatory activity and gastrointestinal tolerability of amtolmetin guacyl, a new NSAID, compared with diclofenac in aged patients with osteoarticular diseases. [Article in Italian] Clin Ter 1997; 148 (11): 543–8.
36. Marcolongo R, Frediani B, Biasi G et al. A Meta-Analysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal Anti-Inflammatory Drug, Compared with Established Agents. Clin Drug Invest 1999; 17 (2): 89–96.
37. Jajić Z, Malaise M, Nekam K et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 (6): 809–18.
38. Belisari A, Mantovani L. Cost-Benefit Analysis of Amtolmetin-Guacil. Clin Drug Invest 2001; 21 (1): 47–58.

А.Е.Каратеев

ФГБУ НИИ ревматологии им. В.А.Насоновой РАМН, Москва